TriangleDISEASE & TREATMENT SETTING
OPDIVO QVANTIG: esophageal cancer (neoadjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
Broader topic: Esophageal Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- neoadjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- who have received neoadjuvant chemoradiotherapy (CRT)
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for OPDIVO QVANTIG (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice